Navigation Links
Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna
Date:9/26/2011

AUSTIN, Texas, Sept. 26, 2011 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX), today announced that it will host Planet xMAP Europe 2011, its annual European multiplexing technology symposium, September 28-29, 2011, at The Hofburg in Vienna, Austria. The event will feature scientific sessions, workshops, discussion groups, exhibitions and networking events with scientists and researchers from around the world who are performing groundbreaking work in clinical diagnostics and life science research using the Luminex xMAP® multiplexing technology platform.  

(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

"Key areas of focus for this year's symposium include pathogen detection, immunology-monitoring, human genetics, protein and nucleic acid research," said Paul C. Ladestein, General Manager European Operations for Luminex. "Planet xMAP Europe is an excellent opportunity for leading scientists to gather and exchange ideas on how xMAP multiplexing technology is revolutionizing their laboratories and research."

xTAG® GPP is only one example of the innovations in molecular diagnostics that highlights this year's agenda. CE marked xTAG GPP, the only test to simultaneously detect and identify up to 95 percent of the disease causing bacterial, viral and gastroenteritis pathogens in a single test, was used as a front-line test during the recent German outbreak of a novel E. coli strain.

Planet xMAP Europe 2011 will feature two days of presentations with focused session options.  

Day One of Planet xMAP Europe 2011, Wednesday, 28 September, will focus on Pathogen Detection, the xTAG Gastrointestinal Pathogen Panel (GPP), Immunology-Monitoring, and HLA-Human Genetics.The morning session will include the following presentations:

Eugene Halligan, Ph.D., St. Thomas' Hospital, London, UK, "An evaluation of the Luminex xTAG® Gastrointestinal Pathogen Panel at a London teaching hospital 2011: The comparative performance of a rapid molecular multiplex assay and current standard laboratory investigations for gastroenteritis"

Matthew Albert, M.D., Head, Laboratory of Dendritic Cell Immunobiology, Director, Department of Immunology, Pasteur Institute, Paris, France, "How biomarker discovery can lead to new insights into disease pathogenesis and new therapeutic targets for chronic HCV infection"

Morten Ruhwald, M.D., Hvidovre Hospital, Copenhagen, Denmark, "Immuno-diagnosis of tuberculosis infection using IP-10"

Prof. Jean-Louis Merlin, Unite de Biologie des Tumeurs, Nancy, France, "Phosphoprotein array assay companion diagnostics for response prediction to monoclonal antibodies and kinase inhibitors in oncology"

Holly Soares, Ph.D., Director Neuroscience Clinical Biomarkers Group, Bristol-Myers Squibb, Wallingford, CT, USA, "Use of multiplex panels to identify novel CSF and plasma biomarkers of Alzheimer's disease"

The afternoon session will feature three separate tracks focused on Human Genetics, Immunology-Monitoring, and Pathogen Detection.

Day Two of Planet xMAP Europe 2011, Thursday, 29 September, will focus on Genomic and Protein Research.The morning session will include the following presentations:

John E. Connolly, Ph.D., Director, Program in Translational Immunology Principal Investigator, Singapore Immunology Network (SIgN), "Systems Approaches to Monitoring Immune Responses in Clinical Trials"

Prof. Dr. Matthias Mack, Institute for Technical Microbiology, Mannheim University of Applied Sciences, Mannheim, Germany, "A high-throughput microtiter plate-based screening method for the detection of full-length recombinant proteins"

Alina Deshpande, Ph.D., D-3, Systems Engineering and Integration Decision, Applications Division, Los Alamos, NM, USA, "Multiplexed Nucleic Acid-Based Assays for Human Disease Diagnosis"

Prof. Christophe Sola, Microbiology and Genetic Institute UMR8621, Orsay University, Paris, France, "CRISPR and RNA characterization on microspheres for academic and operational research in microbiology"

Tom Copa, Vice President, Life Science Research & Food Safety, Luminex Corporation, Austin, TX, USA, "It's About Time"

The afternoon session will feature two separate tracks focused on Genomic Research and Protein Research.

For detailed information regarding the Planet xMAP Europe 2011 symposium and agenda, or to register online, please visit http://www.planetxmap.com. About Luminex CorporationLuminex is committed to applying its passion for innovation to advancing healthcare and research worldwide.  We are transforming global healthcare and life-science research through the development, manufacturing, and marketing of proprietary instruments and assays utilizing our xMAP open-architecture, multi-analyte platform and our MultiCode real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies that deliver cost-effective and rapid results to clinicians and researchers.  Our technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies.  We are meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety.  For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology please visit our website at http://www.luminexcorp.com.Contacts Corporate:

Media:Harriss T. Currie

Mimi TorringtonChief Financial Officer and Vice President, Finance

Director, Marketing CommunicationsLuminex Corporation

Luminex Corporationhcurrie@luminexcorp.com

mtorrington@luminexcorp.com512.219.8020

512.219.8020Investors:Matthew Scalo

Leslie DensonSr. Director, Investor Relations

Porter NovelliLuminex Corporation

Leslie.Denson@porternovelli.commscalo@luminexcorp.com

512.241.2233512.219.8020
'/>"/>

SOURCE Luminex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Luminex Corporation to Present at Upcoming Investment Conferences In September
2. Luminex Corporation Reports Second Quarter 2011 Results
3. Luminex Corporation Receives U.S. FDA Clearance for New, Front Line Respiratory Viral Panel Test
4. Luminex Corporation Second Quarter Earnings Release Scheduled for August 8, 2011
5. Luminex Corporation Completes Acquisition of EraGen Biosciences, Inc.
6. Luminex Corporation Named Most Innovative Company of the Year and Receives Business Innovation of the Year Award for MAGPIX® System
7. Luminex Corporation Announces Agreement to Acquire EraGen Biosciences, Inc.
8. Luminex and Life Technologies Sign Agreement for Global Distribution of the Award-Winning MAGPIX® Multiplexing Instrument
9. Luminex Corporation to Present at Jefferies 2011 Global Healthcare Conference
10. Luminex Corporation Reports First Quarter 2011 Results
11. Luminex Corporation First Quarter Earnings Release Scheduled for May 9, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... Dec. 3, 2016 Johnson & Weaver, LLP announces ... purchasers of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ... October 31, 2016 (the "Class Period"). Zimmer Biomet ... markets orthopaedic reconstructive products, such as knee and hip reconstructive ... , , ...
(Date:12/4/2016)... highly innovative, personalized cell-based treatment for a high-risk form of the most ... Children,s Hospital of Philadelphia today reported new results ... The physician-scientists presented findings at the annual meeting of the ... Continue Reading ... ...
(Date:12/2/2016)... -- bioLytical Laboratories, un líder mundial en test rápidos de enfermedades ... Test , a los miembros de la Kenya Pharmaceutical Association. ... ... HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ... http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical fue invitada por la Clinton Health ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... December 04, 2016 , ... Patients who ... now take advantage of a cosmetic procedure known as Carbon Dioxide (C02) ... the appearance of age spots, fine lines, uneven coloration, wrinkles, scarring, skin ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Halfway through ... Medicine has provided preventative dental services to more than 15,900 children 5 years old ... 5 LA pledged $38 million over a span of five years to Western University ...
(Date:12/2/2016)... ... 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will host the ... the 2016 MPN Heroes—eight individuals who have made a difference in the field of ... standard of care, demonstrating leadership within the MPN community and/or a commitment to individual ...
(Date:12/2/2016)... ... ... Advanced Inc., a leading provider of travel therapy and travel nursing across ... Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served as Vice ... leadership experience to Advanced Inc. He began his career in finance at Ernst & ...
(Date:12/2/2016)... ... , ... The annual time frame to change Medicare health and prescription drug ... 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their current plan to ... make changes during this period order for their new policy to go into effect ...
Breaking Medicine News(10 mins):